NCT04781088: An ongoing trial by Floor Backes, MD
This trial is ongoing. It must report results 6 months, 2 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04781088 |
|---|---|
| Title | Phase II Study With Safety Lead-In of Lenvatinib, Pembrolizumab, and Weekly Paclitaxel for Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 1, 2021 |
| Completion date | July 1, 2025 |
| Required reporting date | July 1, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |